Drugs Made In America Acquisition II (NASDAQ:DMII) Stock Price Down 0.2% – Here’s What Happened

Shares of Drugs Made In America Acquisition II Corp. (NASDAQ:DMII) fell 0.2% on Wednesday . The stock traded as low as $10.08 and last traded at $10.08. Approximately 13,223 shares were traded during trading, a decline of 89% from the average daily volume of 117,632 shares. The stock had previously closed at $10.10.

Wall Street Analyst Weigh In

A number of brokerages have weighed in on DMII. Weiss Ratings raised shares of Drugs Made In America Acquisition II from a “sell (e)” rating to a “sell (e+)” rating in a report on Thursday, June 11th. Wall Street Zen raised shares of Drugs Made In America Acquisition II from a “sell” rating to a “hold” rating in a research note on Sunday, May 10th. One analyst has rated the stock with a Sell rating, According to MarketBeat.com, the stock presently has a consensus rating of “Sell”.

Drugs Made In America Acquisition II Price Performance

The firm’s fifty day simple moving average is $10.07.

Institutional Investors Weigh In On Drugs Made In America Acquisition II

A number of large investors have recently made changes to their positions in DMII. Magnetar Financial LLC acquired a new position in Drugs Made In America Acquisition II in the 4th quarter worth approximately $26,730,000. Glazer Capital LLC acquired a new stake in shares of Drugs Made In America Acquisition II in the fourth quarter worth $23,264,000. First Trust Capital Management L.P. acquired a new stake in shares of Drugs Made In America Acquisition II in the fourth quarter worth $20,474,000. Healthcare of Ontario Pension Plan Trust Fund purchased a new position in shares of Drugs Made In America Acquisition II during the first quarter valued at $19,960,000. Finally, Hudson Bay Capital Management LP acquired a new position in Drugs Made In America Acquisition II during the fourth quarter valued at $19,493,000.

Drugs Made In America Acquisition II Company Profile

Drugs Made In America Acquisition II (NASDAQ:DMII) is a special purpose acquisition company (SPAC) formed to raise capital through a public listing for the purpose of effecting a business combination. As a blank‑check vehicle, the company itself does not operate a traditional commercial business; instead, it seeks to identify, negotiate and complete an acquisition, merger, share exchange, asset purchase or similar business transaction with one or more target companies.

The stated investment focus reflected in the company’s name indicates an emphasis on the pharmaceutical and life sciences sector, with a particular interest in domestic drug manufacturing, supply‑chain resiliency and related healthcare operations in the United States.